Compare KLXE & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KLXE | RNTX |
|---|---|---|
| Founded | 2018 | 2001 |
| Country | United States | United States |
| Employees | N/A | 10 |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.6M | 47.7M |
| IPO Year | 2018 | N/A |
| Metric | KLXE | RNTX |
|---|---|---|
| Price | $2.50 | $1.93 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 236.7K | 123.2K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $636,600,000.00 | N/A |
| Revenue This Year | $3.89 | N/A |
| Revenue Next Year | $4.95 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.46 | $1.02 |
| 52 Week High | $3.45 | $2.22 |
| Indicator | KLXE | RNTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.26 | 71.89 |
| Support Level | $2.14 | $1.08 |
| Resistance Level | $3.10 | $2.18 |
| Average True Range (ATR) | 0.24 | 0.20 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 42.53 | 75.76 |
KLX Energy Services Holdings Inc is a growth-oriented provider of diversified oilfield services to onshore oil and natural gas exploration and production (E&P) companies operating in both conventional and unconventional plays in all of the active basins throughout the United States. It serves the companies engaged in the exploration and development of onshore conventional and unconventional oil and natural gas reserves. Its products and services offerings include surface facilities and equipment, pressure control services, wireline services, fishing services, and engineered products. The company's segments include Southwest; Rocky Mountains and Northeast/Mid-Con region. It derives maximum revenue from Southwest region.
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.